



VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019

April 3, 2019

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2019 / [VistaGen Therapeutics](#) (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that [Shawn Singh, VistaGen's Chief Executive Officer](#), will participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference at the Omni Berkshire Place, New York on Thursday, April 4, 2019.

William Blair 3rd Annual Late-Stage Therapeutics Conference

Omni Berkshire Place, New York, NY

Thursday, April 4, 2019

For more information regarding the conference, or to schedule a one-on-one meeting with VistaGen's management team, please contact KCSA Strategic Communications at VistaGen@KCSA.com or your William Blair representatives directly.

About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. VistaGen's CNS pipeline includes three drug candidates (AV-101, PH10, and PH94B) with potential for at-home use, rapid-onset therapeutic benefits and exceptional safety. Each CNS drug candidate in VistaGen's pipeline is either currently in or has completed Phase 2 clinical development. AV-101, an oral NMDA receptor glycine site antagonist (a full antagonist), is in Phase 2 development in the U.S. for major depressive disorder (MDD) and in a first-step target engagement study in healthy volunteer U.S. military Veterans for suicidal ideation. The FDA has granted Fast Track designation for development of AV-101, both as a potential [adjunctive treatment for MDD](#) and as a [non-opioid treatment for neuropathic pain](#). PH10 is a potential first-in-class neuroactive nasal spray with rapid-onset antidepressant effects observed at microgram doses and without systemic exposure. PH10 is in Phase 2 development for MDD. PH94B is a potential first-in-class neuroactive nasal spray with rapid-onset effects observed at microgram doses and without systemic exposure. Phase 2 and pilot Phase 3 development of PH94B for Social Anxiety Disorder (SAD) has been completed successfully, and PH94B is now being prepared for pivotal Phase 3 development as an on-demand PRN treatment for SAD.

For more information, please visit www.vistagen.com and connect with VistaGen on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Company Contact

Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

Investor Contact

Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com

Media Contact

Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com

SOURCE: VistaGen Therapeutics, Inc.

Released April 3, 2019